Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757038 | 0.79 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL5262431 | 0.78 | ALDH1A1 (0.48) | HPGDSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL5633792 | 0.78 | EHMT2 (0.56) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL3075428 | 0.78 | EHMT2 (0.56) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL12786631 | 0.77 | SMN1; SMN2 (0.43) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL1479297 | 0.76 | ALDH1A1 (0.55) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL7102145 | 0.75 | HPGD (0.42) | HPGDSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL3070731 | 0.75 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL3125142 | 0.75 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL1607377 | 0.74 | LMNA (0.51) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-9808528-B2 | Protein-polymer-drug conjugates and methods of using same | MERSANA THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-8329876-B2 | Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith | NEKTAR THERAPEUTICS (US) | 2012-12-11 | — | — | US | disclosed |
| US-8288351-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120065330-A1 | Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith | NEKTAR THERAPEUTICS (US) | 2012-03-15 | — | — | US | disclosed |
| US-8071678-B2 | Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith | NEKTAR THERAPEUTICS (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110065862-A1 | Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith | NEKTAR THERAPEUTICS (US) | 2011-03-17 | — | — | US | disclosed |
| US-7834088-B2 | Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith | NEKTAR THERAPEUTICS (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100069571-A1 | Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith | NEKTAR THERAPEUTICS (US) | 2010-03-18 | — | — | US | disclosed |
| US-7605120-B2 | peptides and/or conjugated peptides may be used as therapeutics or prophylactics for the treatment of diseases mediated by B1 activation, including inflammation and chronic pain states of inflammatory and neuropathic origin, septic shock, arthritis, osteoarthritis, angina, asthma, allergic rhinitis | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-7511095-B2 | Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, LTB4R | HPGD 1147/4885SMN1; SMN2 3387/4885HSD17B10 4301/4885 |
| US-20100069571-A1 | Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith | PCTP, CETP, NGLY1 | HPGD 1334/4885SMN1; SMN2 4702/4885HSD17B10 1049/4885 |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, AVPR1B | HPGD 944/4885SMN1; SMN2 3416/4885HSD17B10 4290/4885 |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | HPGD 1806/4885SMN1; SMN2 2695/4885HSD17B10 1974/4885 |
| US-20120065330-A1 | Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith | PCTP, CETP, NGLY1 | HPGD 1334/4885SMN1; SMN2 4702/4885HSD17B10 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.